Jennifer  Ku  to  California
                            
                            
                                This is a "connection" page, showing publications  Jennifer  Ku  has written about  California.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.429
         
        
        
     
 
    
        
        - 
            Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults =65 Years of Age. Clin Infect Dis. 2024 Nov 22; 79(5):1283-1292.
            
            
                Score: 0.147
             
- 
            Risk of Corneal Graft Rejection and Vaccination: A Matched Case-Control Study From a United States Integrated Health Care System. Am J Ophthalmol. 2024 07; 263:133-140.
            
            
                Score: 0.140
             
- 
            Development and validation of prediction algorithm to identify tuberculosis in two large California health systems. Nat Commun. 2025 Apr 10; 16(1):3385.
            
            
                Score: 0.038
             
- 
            Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022-2023 Season Among Adults 18-64?Years. Influenza Other Respir Viruses. 2024 Dec; 18(12):e70025.
            
            
                Score: 0.037
             
- 
            Risk Factors for Recurrent Urinary Tract Infections Among Women in a Large Integrated Health Care Organization in the United States. J Infect Dis. 2024 Nov 15; 230(5):e1101-e1111.
            
            
                Score: 0.037
             
- 
            Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021 12 15; 375:e068848.
            
            
                Score: 0.030